GP Health Service Capital and Shanghai Pharmaceuticals to acquire a 45% stake in Shanghai Hutchison Pharmaceuticals from HUTCHMED for $608m.

GP Health Service Capital, a private-equity firm, and Shanghai Pharmaceuticals, a pharmaceutical company, agreed to acquire a 45% stake in Shanghai Hutchison Pharmaceuticals, a company manufacturing, selling and distributing cardiovascular diseases medicines, from HUTCHMED, a commercial‑stage biopharmaceutical company, for $608m. “This transaction to divest most of our holding in SHPL is another example of HUTCHMED delivering on the strategy outlined in 2022, accelerating our path to profitability and focusing on core operations. SHPL is a well-established business, having delivered over US$370 million in dividends to HUTCHMED throughout the years, and we are confident that it continues to have promising future growth prospects. We are focused on capitalizing on our two decades of deep research into oncogenic drivers of disease and discovering and developing highly optimized therapies, through our unique ATTC platform,” Dan Eldar, HUTCHMED Chairman and Non-executive Director.